DOuBLED - Doubling Outcomes by Lung Cancer Early Diagnosis - DOuBLED

Study identifier:D133FR00176

ClinicalTrials.gov identifier:NCT05091437

EudraCT identifier:N/A

CTIS identifier:N/A

Recruitment Complete

Official Title

Doubling Outcomes by Lung Cancer Early Diagnosis: An observational, study to collect real-world evidence (RWE) on the management of pulmonary nodules across Latin-America

Medical condition

Pulmonary nodules

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

562

Study type

Observational

Age

35 Years - 100 Years

Date

Study Start Date: 30 Dec 2021
Estimated Primary Completion Date: 30 Jun 2025
Estimated Study Completion Date: 30 Jun 2025

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

INCUNA (Scientific and Technical partner)

Inclusion and exclusion criteria